Back in March 2020, the U.S. Food and Drug Administration (FDA) announced that it was strengthening the existing warnings about serious behavior and mood-related side effects associated with asthma medication Singulair (montelukast) and its generics. The drug already had warnings about mental health side effects, … Continue reading As the Number of Singulair Lawsuits Increase, NJ Considers Multicounty Litigation